Home
News
Create
Screeners
Insights
Kobo Biotech
8.
90
0.00
(0.00%)
Market Cap
₹21.20 Cr
PE Ratio
-4.05
Industry
Chemicals
Buy
Sell
Company Performance:
1D
0.00%
1M
+22.93%
6M
+292.07%
1Y
+280.34%
5Y
+31.27%
View Company Insights
Latest news about Kobo Biotech
Kobo Biotech shareholders approve FY24 accounts at 31st AGM
1 day ago
Kobo Biotech Limited concluded its 31st Annual General Meeting on July 24, 2026, where shareholders approved the annual accounts for the financial year ended March 31, 2024. The resolution received unanimous support from 17,934 votes cast by non-institutional public investors, while promoter and institutional groups did not participate in the voting process.
Kobo Biotech loss widens to ₹5.23 crore in FY25
Jun 29, 2026
Kobo Biotech narrows net loss to ₹49.29 lakh in FY 2023-24
Jun 29, 2026
NCLT Approves Beaufond Industries' Resolution Plan for Kobo Biotech Limited
May 13, 2026
Kobo Biotech Limited Submits SEBI Compliance Certificate for Quarter Ended March 31, 2026
Apr 15, 2026
More news about Kobo Biotech
15
Apr 26
Kobo Biotech Limited Confirms Non-Large Corporate Status Under SEBI Framework
Kobo Biotech Limited has confirmed to BSE Limited that it does not qualify as a Large Corporate under SEBI's regulatory framework as of March 31, 2026. The confirmation references SEBI circulars SEBI/HO/DDHS/CIR/P/2018/144 and SEBI/HO/DDHS/P/CIR/2021/613 regarding debt securities issuance by large entities. The communication was signed by Resolution Professional IP Namrata Amol Randeri, indicating the company is under corporate insolvency resolution process.
31
Oct 25
Kobo Biotech Limited's Committee of Creditors Approves Multiple Resolutions, Including CIRP Extension and Professional Fees
Kobo Biotech Limited's Committee of Creditors (CoC) has approved several crucial resolutions in its ongoing Corporate Insolvency Resolution Process (CIRP). Key developments include the approval of CVK Technologies Private Limited's resolution plan, extension of CIRP period until January 29, and further extension for submission of resolution plans until April 15, 2025. The CoC also approved Resolution Professional fees, ratified various professional fees, and authorized the forfeiture of a Rs. 1.05 crore deposit from a previous applicant. JM Financial Asset Reconstruction Company Limited holds a 99.12% voting share in the CoC.
31
Oct 25
Kobo Biotech's Committee of Creditors Approves 90-Day Extension for Insolvency Resolution Process
Kobo Biotech Limited's Committee of Creditors (CoC) has approved a 90-day extension for the Corporate Insolvency Resolution Process, moving the deadline to May 14, 2025. The CoC also ratified expenses, appointed legal counsel, approved legal action against Telangana's Commercial Tax Department to recover Rs. 1.97 crores, and extended the timeline for resolution plan submissions to February 8, 2025. Namrata Randeri, the Resolution Professional, has been authorized to operate bank accounts and execute approved resolutions.
Kobo Biotech
8.
90
0.0
(0.0%)
1 Year Returns:
+280.34%
Industry Peers
Deepak Fertilisers & Petrochemicals
1,570.00
(-
0.
20
%)
Tata Chemicals
689.00
(+
0.
53
%)
Gujarat Narmada Valley Fert & Chem
503.00
(-
0.
01
%)
TANFAC Industries
2,702.40
(0.0%)
Gujarat Alkalies & Chemicals
672.90
(-
0.
28
%)
GHCL
433.50
(-
0.
62
%)
Grauer & Weil
74.00
(+
0.
04
%)
Chemplast Sanmar
202.68
(+
0.
19
%)
Fischer Medical Ventures
37.90
(-
0.
11
%)
Thirumalai Chemicals
167.70
(-
0.
02
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar